MEREO BIOPHARMA GROUP PLC (MREO) Return on equity 2022–2025
MEREO BIOPHARMA GROUP PLC (MREO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-102.4%FY2025 · since FY2022: -82.1% → -102.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -102.4% | -31.4 pp |
| FY2024 | -70.9% | -12.6 pp |
| FY2023 | -58.3% | +23.8 pp |
| FY2022 | -82.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MREO financial trends
MREO RevenueMREO Net incomeMREO Net marginMREO Gross profitMREO Gross marginMREO Operating incomeMREO Operating marginMREO Operating cash flowMREO Free cash flowMREO Capital expendituresMREO Stock buybacksMREO Dividends paidMREO Total assetsMREO Total liabilitiesMREO Shareholders’ equityMREO overview →